EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

5‐Methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

5‐Methoxy‐N,N‐dimethyltryptamin (5‐MeO‐DMT) bei Alkoholgebrauchsstörung: offene Phase-2a-Studie mit BPL‐003

John Marsden iD, Michael Kelleher, Fiona Dunbar, Anna O Ermakova iD, Luke Mitcheson, Claire Roberts, James J Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve

Addiction · 10.12.2025

DOI: 10.1111/add.70260 ↗

Auf einen Blick

In einer offenen Phase-2a-Studie bei Menschen mit moderat-schwerer Alkoholgebrauchsstörung war eine Einzeldosis BPL‐003 mit akzeptabler Sicherheit und vorläufigen Hinweisen auf weniger Alkoholkonsum verbunden.

Fragestellung

Welche Sicherheit, Verträglichkeit und ersten Wirksamkeitshinweise zeigt BPL‐003 bei moderat-schwerer Alkoholgebrauchsstörung?

Methode

Offene Phase-2a-Einzeldosisstudie mit 12 Wochen Follow-up; 13 Teilnehmende in 2 Kliniken in England; 10-wöchiges CBT-Programm im Standard of care.

Ergebnisse

12 Teilnehmende in der Wirksamkeitsanalyse. 41 TEAEs, alle leicht oder mittelgradig, bei 11 von 12 (84,6 %); keine TEAE-bedingten Abbrüche. Abstinente Tage stiegen von 33,2 % auf 80,8 %; HDDs sanken von 56,2 % auf 13,2 %.

Einschränkungen

Offenes Design, keine Kontrollgruppe, kleine Stichprobe.

Schlussfolgerung der Autor:innen

Die erste Phase-2a-Studie zeigte akzeptable Sicherheit und Verträglichkeit und erste Wirksamkeitshinweise zur Reduktion von Craving und Konsum; größere kontrollierte Studien werden unterstützt.

Kernaussagen

  • 41 TEAEs, alle leicht oder mittelgradig; keine TEAE-bedingten Abbrüche
  • Abstinente Tage: 33,2 % zu Baseline, 80,8 % in Woche 12
  • Vorläufige Hinweise auf weniger Craving und Alkoholkonsum

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Addiction, online erschienen am 10.12.2025. Verfasst von John Marsden und 10 weiteren Autor:innen. Beteiligte Einrichtung: Addictions Department, School of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beckley Psytech Ltd.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive Behavioural Therapy (CBT).

Design

Open‐label, phase 2a, single‐dose, clinical trial with 12‐week follow‐up (Day 84 endpoint) with a target of 12 participants.

Setting

Two clinics in England between 29 March 2023 and 2 July 2024.

Participants

Thirteen participants were enrolled. Most were male (n = 10; 76.9%), of White‐UK origin (n = 12; 92.3%), with a mean age of 49.3 years. Twelve participants completed the study (efficacy analysis set).

Intervention

Participants received a single intranasal dose of 10 mg BPL‐003 in a controlled environment with psychological support. Participants received three pre‐dose preparation sessions and three post‐dose integration sessions before CBT.

Measurements

Primary endpoints were safety and tolerability (by physical examination, laboratory evaluations, cardiac telemetry and treatment emergent adverse events [TEAEs]). Exploratory endpoints included Timeline Follow‐Back recording of alcohol use (abstinent days, units per day/week, heavy drinking days [HDDs; defined according to the UK government definition of binge drinking: ≥7 units per day women, ≥9 units per day men]) to Week 12 follow‐up (study endpoint); craving, alcohol‐related problems; and patient‐ and clinician‐reported measures of well‐being and health‐related quality of life (HRQoL).

Findings

Over 12 weeks, 41 TEAEs (all mild or moderate in severity) were reported by 11 of 12 (84.6%) participants (no TEAE‐related withdrawals). The most common TEAEs were study drug administration site pain (four participants; 30.8%); transient elevations in blood pressure after drug administration (four participants; 30.8%); and flashbacks (reactivations), nightmares, and nausea (two participants; 15.4%). At Week 12, the mean (standard deviation [SD]) percentage of abstinent days increased from 33.2% (22.8) at baseline to 80.8% (28.2) and HDDs reduced from 56.2% (SD 26.4) at baseline to 13.2% (SD 21.8). Six of 12 participants (50%) were continuously abstinent, three (25%) had meaningful reductions in alcohol consumption, and three (25%) had no change or a limited change in their drinking patterns. Overall, measures of the negative consequences of alcohol, craving, well‐being and HRQoL indicated improvement.

Conclusions

A first phase 2a clinical trial of 5‐methoxy‐N,N‐dimethyltryptamine (BPL‐003 10 mg) in the context of a 10‐week programme of CBT demonstrated acceptable safety and tolerability and provided preliminary evidence of efficacy for reducing alcohol craving and consumption. These findings support progression to larger, controlled trials of BPL‐003 for the treatment of alcohol use disorder.

Schlagwörter

Stichwörter der Autor:innen

5‐MeO‐DMTBPL‐003alcohol use disordercognitive behavioural therapypsychedelicspsychedelic‐assisted treatment

Autor:innen und Institutionen

  • Addictions Department, School of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • South London and Maudsley NHS Foundation Trust, UK.
  • Beckley Psytech, Oxford, UK.
  • Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

ORCID-Profile: John Marsden, Anna O Ermakova

Förderung

  • Beckley Psytech Ltd

Zitieren

APA

Marsden, J., Kelleher, M., Dunbar, F., Ermakova, A. O., Mitcheson, L., Roberts, C., Rucker, J. J., Scott, G., Saeger, I., Small, F., & Seynaeve, M. (2025). 5‐Methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial. Addiction. https://doi.org/10.1111/add.70260

Vancouver

Marsden J, Kelleher M, Dunbar F, Ermakova AO, Mitcheson L, Roberts C, et al. 5‐Methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial. Addiction. 2025. doi:10.1111/add.70260

BibTeX
@article{Marsden2025,
  author = {Marsden, John and Kelleher, Michael and Dunbar, Fiona and Ermakova, Anna O and Mitcheson, Luke and Roberts, Claire and Rucker, James J and Scott, Gemma and Saeger, Ivan and Small, Francesca and Seynaeve, Mathieu},
  title = {5‐Methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial},
  journal = {Addiction},
  year = {2025},
  doi = {10.1111/add.70260}
}
Kostenlos starten →